Arkolith/Insider Trading/XLO/Form 4

Russo Rene

PRESIDENT AND CEO, DirectorXilio Therapeutics, Inc. (XLO) · full profile →Form 4 · filed Nov 25, 2025
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
17
0 non-derivative · 17 derivative

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Nov 21, 2025Disposed to issuer(D)150K——0
Nov 21, 2025Grant(A)350K——350K
Nov 21, 2025Disposed to issuer(D)473K——0
Nov 21, 2025Grant(A)240K——240K
Nov 21, 2025Disposed to issuer(D)240K——0
Nov 21, 2025Grant(A)2.1M—$02.1M
Nov 21, 2025Grant(A)473K——473K
Nov 21, 2025Disposed to issuer(D)135K——0
Nov 21, 2025Grant(A)135K——135K
Nov 21, 2025Disposed to issuer(D)50K——0
Nov 21, 2025Grant(A)50K——50K
Nov 21, 2025Disposed to issuer(D)100K——0
Nov 21, 2025Grant(A)100K——100K
Nov 21, 2025Disposed to issuer(D)350K——0
Nov 21, 2025Grant(A)700K——700K
Nov 21, 2025Disposed to issuer(D)700K——0
Nov 21, 2025Grant(A)150K——150K

Transaction Codes

D
Disposition to the issuer
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001193125-25-297203) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML